Damora Therapeutics (DMRA) risk factors
Item 1A of every Damora Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors68 risks57 new88 dropped11 reworded
The company completed the acquisition of Pre-Acquisition Damora in November 2025 and shifted its pipeline focus to lead asset DMR-001 targeting mutCALR-driven MPNs. As a preclinical-stage biotech, operations are funded by $257.6 million in cash expected to last into Phase 3 development.
Filed Mar 19, 2026 - FY2024 10-K risk factors99 risks
Damora Therapeutics transitioned to oncology and liver diseases with GB3226 and GB1211 following the October 2024 Bridge Medicines transaction. The company faces a going concern warning, net losses of $21.4 million in 2024, and severe capital constraints with a public float of only $7.3 million.
Filed Mar 19, 2025